DM0000: The mark consists of the stylized wording "NATACYN" positioned above the wording (natamycin ophthalmic suspension) 5%.
GS0051: Pharmaceutical compositions for ophthalmological use containing natamycin; topical antifungal compositions for ophthalmological use containing natamycin
CC0000: Color is not claimed as a feature of the mark.
DS0000: natamycin
Case File Event Statements
2/12/2024 - 11 months ago
1 - NEW APPLICATION ENTEREDType:NWAP
6/18/2024 - 7 months ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTEREDType:NWOS
9/5/2024 - 4 months ago
3 - ASSIGNED TO EXAMINERType:DOCK
9/12/2024 - 4 months ago
6 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILEDType:GNEN
9/12/2024 - 4 months ago
4 - EXAMINERS AMENDMENT -WRITTENType:CNEA
9/12/2024 - 4 months ago
7 - EXAMINER'S AMENDMENT ENTEREDType:XAEC
9/17/2024 - 4 months ago
8 - APPROVED FOR PUB - PRINCIPAL REGISTERType:CNSA
9/12/2024 - 4 months ago
5 - EXAMINERS AMENDMENT E-MAILEDType:GNEA
10/1/2024 - 4 months ago
9 - WITHDRAWN FROM PUB - OG REVIEW QUERYType:PBCR
10/7/2024 - 3 months ago
13 - NOTIFICATION OF NON-FINAL ACTION E-MAILEDType:GNRN
10/7/2024 - 3 months ago
12 - NON-FINAL ACTION E-MAILEDType:GNRT
1/7/2025 - 24 days ago
15 - CORRESPONDENCE RECEIVED IN LAW OFFICEType:CRFA
1/7/2025 - 24 days ago
14 - TEAS RESPONSE TO OFFICE ACTION RECEIVEDType:TROA